BACKGROUND: Lymphoseek is a molecular imaging agent specifically designed for sentinel lymph node mapping. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for melanoma sentinel lymph node detection. METHODS: Twenty-four patients (33-81 years) with melanoma participated in this study. Four groups of six patients received an intradermal administration (.5 mCi) of 1.0, 5.0, or 10.0 nmol of (99m)Tc-labeled Lymphoseek or filtered [(99m)Tc]sulfur colloid. The injection site clearance was monitored by nuclear imaging for 3 hours. Lymph nodes obtained by gamma-guided biopsy (4.0-8.7 hours after injection) were assayed for radioactivity. Clinical chemistry values were monitored (before injection, before surgery, and 4 and 24 hours), and whole-body scans were acquired at 1 and 12 hours after injection. RESULTS: Lymphoseek exhibited a significantly (P < .001) faster injection site clearance at all dose levels. The mean Lymphoseek clearance half-time was 2.17 +/- .96 hours (n = 18) compared with 14.7 +/- 6.3 hours for fTcSC (n = 6). The mean sentinel lymph node uptakes of Lymphoseek (.73% +/- .94%) and fTcSC (.85% +/- 1.19%) were statistically equivalent (P = .68). Lymphoseek exhibited a lower mean number of sentinel lymph nodes per basin (1.6) than fTcSC (1.9). No adverse events were observed, nor were any clinically significant alterations in laboratory parameters. Radiation absorbed doses were lower than filtered [(99m)Tc]sulfur colloid. CONCLUSIONS: The molecular imaging agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with filtered [(99m)Tc]sulfur colloid.
BACKGROUND:Lymphoseek is a molecular imaging agent specifically designed for sentinel lymph node mapping. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for melanoma sentinel lymph node detection. METHODS: Twenty-four patients (33-81 years) with melanoma participated in this study. Four groups of six patients received an intradermal administration (.5 mCi) of 1.0, 5.0, or 10.0 nmol of (99m)Tc-labeled Lymphoseek or filtered [(99m)Tc]sulfur colloid. The injection site clearance was monitored by nuclear imaging for 3 hours. Lymph nodes obtained by gamma-guided biopsy (4.0-8.7 hours after injection) were assayed for radioactivity. Clinical chemistry values were monitored (before injection, before surgery, and 4 and 24 hours), and whole-body scans were acquired at 1 and 12 hours after injection. RESULTS:Lymphoseek exhibited a significantly (P < .001) faster injection site clearance at all dose levels. The mean Lymphoseek clearance half-time was 2.17 +/- .96 hours (n = 18) compared with 14.7 +/- 6.3 hours for fTcSC (n = 6). The mean sentinel lymph node uptakes of Lymphoseek (.73% +/- .94%) and fTcSC (.85% +/- 1.19%) were statistically equivalent (P = .68). Lymphoseek exhibited a lower mean number of sentinel lymph nodes per basin (1.6) than fTcSC (1.9). No adverse events were observed, nor were any clinically significant alterations in laboratory parameters. Radiation absorbed doses were lower than filtered [(99m)Tc]sulfur colloid. CONCLUSIONS: The molecular imaging agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with filtered [(99m)Tc]sulfur colloid.
Authors: Sean P Stroup; Christopher J Kane; Salman Farchshchi-Heydari; Claude M James; Christopher H Davis; Anne M Wallace; Carl K Hoh; David R Vera Journal: Clin Exp Metastasis Date: 2012-06-20 Impact factor: 5.150
Authors: Hak J Lee; Christopher V Barback; Carl K Hoh; Zhengtao Qin; Kareem Kader; David J Hall; David R Vera; Christopher J Kane Journal: J Nucl Med Date: 2017-02-02 Impact factor: 10.057
Authors: Ava Hosseini; Jennifer L Baker; Christopher A Tokin; Zhengtao Qin; David J Hall; Dwayne G Stupak; Tomoko Hayashi; Anne M Wallace; David R Vera Journal: J Surg Res Date: 2014-05-10 Impact factor: 2.192
Authors: Frederick O Cope; Bonnie Abbruzzese; James Sanders; Wendy Metz; Kristyn Sturms; David Ralph; Michael Blue; Jane Zhang; Paige Bracci; Wiam Bshara; Spencer Behr; Toby Maurer; Kenneth Williams; Joshua Walker; Allison Beverly; Brooke Blay; Anirudh Damughatla; Mark Larsen; Courtney Mountain; Erin Neylon; Kaeli Parcel; Kapil Raghuraman; Kevin Ricks; Lucas Rose; Akhilesh Sivakumar; Nicholas Streck; Bryan Wang; Christopher Wasco; Larry S Schlesinger; Abul Azad; Murugesan V S Rajaram; Wael Jarjour; Nicholas Young; Thomas Rosol; Amifred Williams; Michael McGrath Journal: Nucl Med Biol Date: 2015-12-03 Impact factor: 2.408
Authors: Anna M Marcinow; Nathan Hall; Eric Byrum; Theodoros N Teknos; Matthew O Old; Amit Agrawal Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-09 Impact factor: 6.223
Authors: Zhengtao Qin; David J Hall; Michael A Liss; Carl K Hoh; Christopher J Kane; Anne M Wallace; David R Vera Journal: J Biomed Opt Date: 2013-10 Impact factor: 3.170